KU-55933: Potent and Selective ATM Kinase Inhibitor for DNA Damage Response Research

Executive Summary: KU-55933 is a highly selective inhibitor of ATM kinase, exhibiting an IC₅₀ of 13 nM and Ki of 2.2 nM in vitro (ApexBio). It inhibits ATM-dependent phosphorylation of Akt at Ser473, suppressing downstream survival signals and inducing G1 cell cycle arrest through downregulation of cyclin D1 (Zhen et al., 2023). KU-55933 demonstrates approximately 50% inhibition of proliferation at 10 μM in MDA-MB-453 and PC-3 cancer cell lines. It alters cellular metabolism by increasing lactate and glucose consumption while reducing ATP levels in MCF-7 cells. These properties make KU-55933 a preferred tool for dissecting ATM signaling and DNA damage checkpoint regulation in oncology and genome integrity research.

Biological Rationale

ATM kinase orchestrates the cellular response to DNA double-strand breaks (DSBs) by phosphorylating key substrates, including Akt, p53, and H2AX. This cascade preserves genome stability and cell viability (Zhen et al., 2023). Dysregulation of ATM pathways is associated with cancer predisposition syndromes such as ataxia-telangiectasia and with therapy resistance in tumors. Inhibition of ATM kinase activity by selective molecules like KU-55933 enables precise dissection of ATM-dependent signaling in DNA damage checkpoint control, apoptosis, and metabolic adaptation. Moreover, recent studies reveal that ATM interacts with nuclear cGAS, influencing retrotransposon repression and genome stability (Zhen et al., 2023), highlighting broader implications in aging and tumorigenesis.

Mechanism of Action of KU-55933 (ATM Kinase Inhibitor)

KU-55933 is an ATP-competitive inhibitor that binds the active site of ATM kinase with nanomolar affinity (IC₅₀: 13 nM; Ki: 2.2 nM) (ApexBio). Its selectivity profile demonstrates negligible inhibition of related PI3K-like kinases, including DNA-PK, PI3K, PI4K, ATR, and mTOR at relevant concentrations. Upon ATM inhibition, KU-55933 blocks phosphorylation of several ATM substrates, such as Akt at Ser473, H2AX, and p53, leading to suppression of DNA damage-induced survival signaling (Zhen et al., 2023). This action induces G1 cell cycle arrest, largely through downregulation of cyclin D1 and prevents checkpoint adaptation. Metabolically, KU-55933 increases glycolytic flux (higher lactate), stimulates glucose consumption, and reduces ATP levels, as shown in MCF-7 cells (ApexBio).

Evidence & Benchmarks

• KU-55933 inhibits ATM kinase activity with an IC₅₀ of 13 nM and Ki of 2.2 nM in vitro (ApexBio).
• In MDA-MB-453 and PC-3 cell lines, 10 μM KU-55933 results in ~50% reduction in cell proliferation in 48-hour assays (ApexBio).
• ATM-selective inhibition is confirmed by lack of effect on DNA-PK, PI3K, PI4K, ATR, and mTOR at up to 10 μM (ApexBio).
• KU-55933 suppresses ATM-mediated Akt phosphorylation at Ser473, validated by immunoblot and phospho-specific antibody staining (Zhen et al., 2023).
• Treatment increases lactate and glucose consumption, and decreases ATP in MCF-7 cells after 24 hours at 10 μM (ApexBio).
• KU-55933 is insoluble in water and ethanol but is soluble at ≥41.67 mg/mL in DMSO with gentle warming (ApexBio).
• ATM inhibition by KU-55933 sensitizes cells to DNA-damaging agents, supporting ATM's role in DNA damage checkpoint signaling (Zhen et al., 2023).

Applications, Limits & Misconceptions

• DNA damage response research: KU-55933 enables targeted inhibition of ATM in models of DNA double-strand break repair, allowing elucidation of checkpoint and repair dynamics.
• Cancer biology: The compound is used to suppress proliferation and survival in ATM-dependent tumor models, often in combination with genotoxic therapies.
• Metabolic modulation: KU-55933 alters glycolytic and ATP production pathways, providing a tool for studying ATM's metabolic roles.
• Genome stability and cGAS signaling: Recent studies link ATM inhibition to changes in cGAS-mediated retrotransposon repression, implicating KU-55933 in research on genome integrity and aging (Zhen et al., 2023).
• KU-55933 is a reference tool for dissecting ATM's role relative to other PI3K-like kinases due to its high selectivity (ApexBio).

Common Pitfalls or Misconceptions

• Not effective in ATM-null backgrounds: KU-55933 requires functional ATM; it has no effect in ATM knockout or null cell lines.
• Does not inhibit ATR or DNA-PK at research concentrations: It cannot substitute for ATR or DNA-PK inhibitors in related pathways.
• Not suitable for in vivo use without formulation optimization: Poor water/ethanol solubility limits systemic delivery; DMSO stock is standard for in vitro applications only.
• Long-term solution storage leads to loss of potency: Solutions should be freshly prepared; stock is stable at -20°C for several months, but repeated freeze-thaw cycles are discouraged.
• KU-55933 is not a therapeutic drug: This compound is for research use only; it is not approved for clinical or diagnostic applications.

This article extends the foundational overview in KU-55933: A Next-Generation ATM Kinase Inhibitor for Precision DDR Studies by providing updated evidence on cell line benchmarks and metabolic modulation. It also clarifies cGAS-ATM signaling intersections noted in KU-55933: ATM Kinase Inhibitor Unveils New Frontiers in Genome Stability, adding detail on post-translational regulation. For application troubleshooting, see KU-55933: Potent ATM Kinase Inhibitor for DNA Damage Response for advanced workflow strategies.

Workflow Integration & Parameters

• Preparation: Dissolve KU-55933 in DMSO to prepare a ≥41.67 mg/mL stock. Warm gently if needed. Avoid water and ethanol due to insolubility (ApexBio).
• Storage: Store solid desiccated at -20°C. Stock solutions are stable below -20°C for several months. Use solutions promptly after dilution; avoid repeated freeze-thaw cycles.
• Usage: Typical experimental concentrations range from 1–10 μM in cell culture. Adjust according to cell line, endpoint, and sensitivity. Controls should match DMSO vehicle concentrations.
• Readouts: ATM activity can be monitored by immunoblot for phospho-Akt (Ser473), γH2AX, p53-P, or cell cycle/cell proliferation assays.
• Compatibility: Combine with DNA-damaging agents to study checkpoint abrogation or synthetic lethality. Validate specificity in ATM-deficient or wild-type matched models.

Conclusion & Outlook

KU-55933 is a benchmark compound for selective ATM kinase inhibition in DNA damage response, cell cycle, and cancer research. Its high potency, selectivity, and reproducibility enable mechanistic dissection of ATM signaling and checkpoint control. Recent advances connect ATM inhibition to cGAS-mediated genome stability regulation, broadening its relevance to aging and retrotransposon biology. For up-to-date product details and ordering, see the A4605 kit. Ongoing studies continue to expand the applications of KU-55933 in functional genomics, metabolic profiling, and translational oncology.